

**INFORMATIONS CONCERNING THE RIGHTS OF SHAREHOLDERS PURSUANT TO
ARTICLES 7:130 AND 7:139 OF THE COMPANY AND ASSOCIATIONS CODE ON THE
OCCASION OF THE EXTRAORDINARY GENERAL MEETING AND THE EXTRAORDINARY
GENERAL MEETING OF DEFICIENCY TO BE HELD ON 2 APRIL 2020 AT
17 A.M. AT BRUSSELS**

**1. RIGHT OF THE SHAREHOLDERS TO INCLUDE ITEMS ON THE AGENDA AND TO
SUBMIT DECISIONS' PROPOSALS**

Pursuant to article 57:130 of the Company and Associations Code, one or more shareholders holding together at least 3% of the share capital of the Company may (i) request the inclusion of items on the agenda to be addressed at the extraordinary general meeting, and (ii) submit decisions' proposals concerning items to be addressed included or to be included on the agenda of the extraordinary general meeting.

The shareholder or the shareholders exercising this right must, in order for their request to be considered at the general meeting, fulfil the following two cumulative conditions:

- prove that they hold the required share capital set out above at the date of their request (either by a certificate recording the registration of the corresponding shares in the Company's register of registered shares, or by a certificate delivered by the certified account holder or settlement institution, certifying the registration in the accounts, in their name, of the number of corresponding dematerialized shares); and
- still be (a) shareholder(s) with 3% of the Company's share capital at the Record Date (**19 March 2020 at midnight, Belgian time**).

The shareholders may then exercise this right by making their request at the Company in writing by providing the text of the subjects to be dealt with and the proposals for decision relating thereto, or the text of the proposals for decisions to be reflected in the agenda, by indicating the postal or electronic address to which the Company will send the confirmation of receipt of such request. This request must be received by the Company no later than **11 March 2020**, either by mail to frank.hazevoets@biotech.be, by fax to + 32 2 264 03 99 or by ordinary letter at the attention of M. Frank HAZEVOETS, 7 Rue des Chasseurs Ardennais at B-4031 Angleur. The Company will acknowledge receipt of the requests within 48 hours after receipt.

The Company will publish the agenda completed with the additional items to be covered and the related proposals for decisions relating thereto and/or proposals for decisions, which would have been made alone, no later than **18 March 2020** (on the website of the Company at the address www.asitbiotech.com, in the Belgian Official Gazette and in the press).

The proxy form filled out with the additional items to be discussed and the proposals for decisions that would have been placed on the agenda and/or the proposals for decisions, which would have been made alone, will be available on the Company's website at the following address: www.asitbiotech.com, at the same time as the publication of the completed agenda, namely **18 March 2020** at the latest.

However, the proxies that have been notified to the Company before the publication of the completed agenda remain valid for the subjects to be dealt with on the agenda that they cover. By way of an exception to the foregoing, for the subjects to be dealt with on the agenda which are the subject of new proposals for decisions filed in accordance with article 533ter of the Company Code, the proxy holder may, at the general meeting, depart from the instructions given by his proxy grantor, if carrying out these instructions could prejudice

the interests of his proxy grantor. The proxy holder must inform his proxy grantor of this. The proxy must indicate whether the proxy holder is entitled to vote on matters newly included on the agenda or whether he or she should abstain.

2. RIGHT OF SHAREHOLDERS TO ASK QUESTIONS

Pursuant to article 7:139 of the Company and Associations Code, the shareholders, the holders of convertible bonds of registered subscription rights have the right to ask questions to the Company's directors, at the meeting or in writing, about items placed on the agenda, who will reply to them insofar as the communication of data or facts is not likely to prejudice the Company or confidentiality commitments entered into by the Company or its directors.

The shareholders, the holders of convertible bonds of registered subscription rights also have the right to ask questions to the Company's statutory auditors, at the meeting or in writing, about items placed on the agenda who will reply to them insofar the communication of data or facts is not likely to prejudice the Company's commercial interests or confidentiality commitments entered into by the Company. The directors and the statutory auditors can provide a global answer to several questions with the same subject.

Prior to the extraordinary general meeting to be held on 2 April 2020, as from the publication of the convening notice, shareholders, the holders of convertible bonds of registered subscription rights may put these questions in writing to the directors and statutory auditors, to whom they will be answered, as the case may be, by the directors or the auditors during the meeting.

To exercise this right, shareholders must have complied with the formalities for admission to the meeting, as specified in the convening notice for the general meeting.

These questions can be submitted to the Company by email to frank.hazevoets@biotech.be, by fax to + 32 2 264 03 99 or by ordinary letter at M. Frank HAZEVOETS, 7 Rue des Chasseurs Ardennais at B-4031 Angleur. They must be received by the Company on **27 April 2020 at 5.00 p.m.** (Belgian time) at the latest.

* * *